---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-136386"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:04:20.786898+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MindMed doses first patient in Phase 3 Voyage study of MM120 for GAD

## Summary
- First-ever Phase 3 study of lysergide D-tartrate (LSD) for GAD; primary endpoint HAM-A change at week 12 vs placebo.
- Voyage study to enroll ~200 participants in US; topline data from 12-week double-blind period expected H1 2026.
- Builds on positive Phase 2b study results presented at APA Annual Meeting in May 2024; second Phase 3 Panorama study on track for H1 2025.
- MM120 ODT is a pharmaceutically optimized form of LSD; study includes 52-week duration with 40-week open-label extension.

## SEC filing metadata
- accession: 0000950170-24-136386
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017024136386/0000950170-24-136386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017024136386/mnmd-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-136386
- JSON: https://secwatch.observer/filing/0000950170-24-136386.json
- Plain text: https://secwatch.observer/filing/0000950170-24-136386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.